Quest Diagnostics
About: Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Employees: 56,000
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
126% more first-time investments, than exits
New positions opened: 140 | Existing positions closed: 62
15% more capital invested
Capital invested by funds: $14.9B [Q4 2024] → $17.2B (+$2.26B) [Q1 2025]
7% more funds holding
Funds holding: 881 [Q4 2024] → 943 (+62) [Q1 2025]
2.91% more ownership
Funds ownership: 88.62% [Q4 2024] → 91.53% (+2.91%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
5% less repeat investments, than reductions
Existing positions increased: 311 | Existing positions reduced: 329
39% less call options, than puts
Call options by funds: $83.5M | Put options by funds: $136M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
JP Morgan Lisa Gill | 13%upside $190 | Neutral Maintained | 6 May 2025 |
Piper Sandler David Westenberg | 19%upside $200 | Neutral Maintained | 28 Apr 2025 |
Truist Securities David Macdonald | 13%upside $190 | Hold Maintained | 23 Apr 2025 |
Barclays Stephanie Davis | 10%upside $185 | Equal-Weight Maintained | 23 Apr 2025 |
Evercore ISI Group Elizabeth Anderson | 7%upside $180 | In-Line Maintained | 23 Apr 2025 |
Financial journalist opinion
Based on 10 articles about DGX published over the past 30 days
